A577-nm Pro -Yellow Laser In Treatment of Striae Rubra

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05598190

Enrollment

Registered

2022-10-28

Start date

2022-09-15

Completion date

2023-09-30

Last updated

2022-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Striae Rubra

Brief summary

Stretch marks or striae are common skin condition occurring in both genders, but they are more prevalent among women. These are linear dermal scars that are accompanied by epidermal atrophy. They usually occur frequently in numerous physiological and pathological conditions, such as adolescent growth, pregnancy, obesity, Cushing disease, Marfan syndrome, and long-term systemic or topical steroid use. Decreased expression of collagen and fibronectin genes has also been associated with striae. The pro-yellow laser systems can be used in a wide range of indications such as facial erythema, facial telangiectasia, port wine stain nevus, rosacea, poikilo derma civatte, and Becker's nevus Some of these indications are clinical lesions in the vascular pattern; some are related to the factors that trigger vascularity, such as vascular endothelial growth factor (VEGF) in etiopathogenesis

Interventions

DEVICEPro-Yellow laser 577

4 session for cases with digtal photo before and after sessions

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Yes

Inclusion criteria

* .Patients diagnosed with striae rubera. .Age groups: at any age. .Sex : ( females). * Co-operative patient

Exclusion criteria

* Pregnancy . * Patient using drugs exacerbating stria as topical or systemic steroid, and patients using other forms of treatment for stria as topical tretinoin, emollients, glycolic acid peel and laser, because that might affect the result of our study. * Stria Alba. * Skin infection (viral, bacterial or parasitic). * Immunosuppressed patients or with history of malignancy or radiation therapy and chronic debilitating diseases and Cushing syndrome. * Hypersensitivity to light and intak of photosensitizing drugs.

Design outcomes

Primary

Measure	Time frame	Description
dermoscopic change of width of striae rubrae	1 year	dermoscopic photo for width of striae

Countries

Egypt

Contacts

Primary Contactsoha A abdelal, resident doctor

sohaalaa.2244@azhar.edu.eg01008189033

Backup ContactRefaat R Hammed, professor

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026